Personalis, Inc. Common Stock
PSNL
$15.79
+5.06%
Personalis, Inc. is a genomic sequencing and analytics company that supports the development of personalized cancer vaccines and next-generation immunotherapies. It operates as a niche player in the precision oncology diagnostics industry, differentiating itself through its ImmunoID NeXT platform and NeXT Personal test. The current investor narrative centers on the company's turnaround story, driven by recent revenue stabilization and a sharp stock rally, though ongoing losses and a reliance on partnership-driven growth remain key debates.…
PSNL
Personalis, Inc. Common Stock
$15.79
Investment Opinion: Should I buy PSNL Today?
Rating: Hold. The thesis is that Personalis has strong momentum and a clean balance sheet, but extreme valuation and deteriorating fundamentals warrant caution. The analyst consensus is 2 Buy and 1 Hold, but without an average target price, the implied upside is unclear.
Supporting Evidence: The trailing PS ratio of 42.9x is far above the industry average of 5.0x, indicating extreme overvaluation. Revenue declined 24.9% YoY in Q1 2026, and gross margin fell to 1.8%. The company is unprofitable with a net loss of $30.03 million and negative free cash flow of $25.67 million in Q1. However, analysts expect revenue to grow to $227.4 million, which would justify a forward PS of 21.4x—still a premium but less extreme.
Risks & Conditions: The Hold rating would upgrade to Buy if the stock pulls back to a PS ratio below 20x (price ~$7.36) or if revenue growth accelerates above 30% YoY. It would downgrade to Sell if revenue continues to decline or if gross margins remain below 10%. Overall, the stock appears overvalued relative to its history and peers, and the risk/reward is unfavorable at current levels.
Sign up to view all
PSNL 12-Month Price Forecast
The AI assessment is bearish with medium confidence. The extreme valuation premium (42.9x PS) is unsustainable given the deteriorating fundamentals—revenue decline, margin compression, and persistent losses. While the stock has strong momentum, the risk of a sharp correction is high. The base case of modest growth is already priced in, leaving little upside. A downgrade to a more bearish stance would occur if revenue growth fails to materialize in the next quarter; an upgrade would require evidence of a sustainable path to profitability.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Personalis, Inc. Common Stock's 12-month outlook, with a consensus price target around $12.57 and implied upside of -20.4% versus the current price.
Average Target
$12.57
0 analysts
Implied Upside
-20.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$10 - $18
Analyst target range
Only 3 analysts cover Personalis, with a consensus recommendation leaning bullish (2 Buy, 1 Hold). The average target price is not provided, but based on the estimated EPS of -$0.47 and revenue of $227.4 million, the implied upside/downside cannot be calculated without explicit targets. The limited coverage implies the stock is a small-cap with lower institutional interest, leading to higher volatility and less efficient price discovery. The ratings show recent reaffirmations: Morgan Stanley maintains Equal Weight, while BTIG and Needham reiterate Buy, indicating a cautiously optimistic sentiment. The lack of a wide target range suggests moderate conviction, but the small analyst base means price moves may be more driven by news flow than analyst revisions.
Drowning in data?
Find the real signal!
Bulls vs Bears: PSNL Investment Factors
Personalis presents a high-risk, high-reward profile. The bull case rests on strong technical momentum, low debt, and analyst expectations of revenue growth, while the bear case highlights extreme valuation (42.9x PS vs. industry 5.0x), persistent losses, and declining revenue. Currently, the bearish evidence is stronger due to the unsustainable valuation and deteriorating fundamentals. The single most important tension is whether the company can deliver the revenue growth needed to justify its premium valuation—if it fails, multiple compression could lead to severe downside.
Bullish
- Strong Momentum and Technical Breakout: The stock has surged 150.2% over the past year and is trading at $15.79, near its 52-week high of $16.15. The 1-month gain of 61.3% and 3-month gain of 137.1% far outpace the S&P 500's returns of 0% and 7.6%, respectively, indicating powerful momentum and a potential breakout phase.
- Low Debt and Strong Liquidity: Personalis has a debt-to-equity ratio of 0.15 and a current ratio of 6.76, indicating minimal leverage and ample short-term liquidity. This provides a financial cushion to fund operations and R&D without immediate risk of distress.
- Revenue Growth Expected by Analysts: Analysts estimate revenue of $227.4 million for the next fiscal year, implying a significant increase from the trailing twelve-month revenue of approximately $64.5 million. This expectation of growth is a key driver of the bull case.
- Analyst Consensus Leaning Bullish: With 2 Buy ratings and 1 Hold from 3 analysts, the consensus is cautiously optimistic. The limited coverage suggests potential for positive surprises if the company executes on its turnaround.
Bearish
- Extreme Valuation Premium: The trailing PS ratio of 42.9x is 758% above the industry average of 5.0x, and near the top of its historical range (2.8x to 51.3x). This implies the market is pricing in aggressive future growth, leaving no room for error.
- Persistent Losses and Negative Cash Flow: The company reported a net loss of $30.03 million in Q1 2026 and negative free cash flow of $25.67 million for the quarter. The trailing twelve-month free cash flow is -$84.65 million, indicating reliance on external financing.
- Declining Revenue and Margin Compression: Revenue declined 24.9% year-over-year in Q1 2026 to $15.47 million, and gross margin collapsed to 1.8% from 27.6% in Q2 2025. Operating margin worsened to -207.9%, reflecting severe cost pressures.
- High Volatility and Overextension Risk: With a beta of 2.24, the stock is 124% more volatile than the market. The rapid 150% rally in one year and 61% in one month suggests potential overextension, increasing the risk of a sharp pullback.
PSNL Technical Analysis
Personalis is in a powerful uptrend, with the stock surging 150.2% over the past year and currently trading at $15.79, near the top of its 52-week range of $3.84 to $16.15 (97.8% of the range). This positioning near highs suggests strong momentum but also potential overextension, as the stock has already priced in significant optimism. Short-term momentum is exceptionally strong, with a 1-month gain of 61.3% and a 3-month gain of 137.1%, far outpacing the S&P 500's 1-month and 3-month returns of 0% and 7.6%, respectively. This acceleration from the longer-term trend indicates a breakout phase, though the rapid pace raises the risk of a mean-reversion pullback. The stock's beta of 2.24 implies it is 124% more volatile than the market, amplifying both upside and downside risks. Key support lies at the 52-week low of $3.84, while resistance is at the 52-week high of $16.15. A breakout above $16.15 would signal a continuation of the uptrend, while a breakdown below recent support near $13 could indicate a reversal.
Beta
2.24
2.24x market volatility
Max Drawdown
-55.2%
Largest decline past year
52-Week Range
$4-$16
Price range past year
Annual Return
+150.2%
Cumulative gain past year
| Period | PSNL Return | S&P 500 |
|---|---|---|
| 1m | +61.3% | +0.6% |
| 3m | +137.1% | +6.3% |
| 6m | +59.7% | +9.1% |
| 1y | +150.2% | +20.9% |
| ytd | +101.1% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PSNL Fundamental Analysis
Revenue has been volatile, with Q1 2026 revenue of $15.47 million declining 24.9% year-over-year, following a pattern of sequential declines from $20.61 million in Q1 2025. The multi-quarter trend shows deceleration, with Q2 2025 revenue at $17.20 million and Q3 2025 at $14.50 million, indicating lumpy revenue from pharma partnerships. The company remains unprofitable, with a net loss of $30.03 million in Q1 2026 and a gross margin of just 1.8%, down from 27.6% in Q2 2025, reflecting cost pressures. Operating margin worsened to -207.9% in Q1 2026 from -126.7% in Q2 2025, highlighting margin compression. The balance sheet shows a debt-to-equity ratio of 0.15 and a current ratio of 6.76, indicating low leverage and ample liquidity. However, free cash flow was negative $25.67 million in Q1 2026, and the trailing twelve-month free cash flow is -$84.65 million, meaning the company relies on external financing (equity raises) to fund operations. ROE is -31.1%, reflecting persistent shareholder value destruction.
Quarterly Revenue
$15472000.0B
2026-03
Revenue YoY Growth
-24.9%
YoY Comparison
Gross Margin
1.8%
Latest Quarter
Free Cash Flow
$-84648000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PSNL Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 42.9x based on the latest quarter's annualized revenue, while the forward PS ratio is approximately 21.4x using estimated revenue of $227.4 million. The gap between trailing and forward PS suggests the market expects significant revenue growth. Compared to the industry average PS ratio of 5.0x (estimated), Personalis trades at a 758% premium, reflecting its high-growth narrative but also extreme valuation risk. Historically, the PS ratio has ranged from 2.8x (Q2 2024) to 51.3x (Q2 2021), and the current 42.9x is near the top of its historical band, indicating the market is pricing in optimistic future growth. This level suggests that any disappointment in revenue growth could lead to multiple compression.
PE
-8.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-8.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Personalis faces significant financial risks from its persistent losses and negative cash flow. In Q1 2026, the net loss was $30.03 million and free cash flow was -$25.67 million, with a trailing twelve-month free cash flow of -$84.65 million. The gross margin plummeted to 1.8% from 27.6% in Q2 2025, indicating severe cost pressures. The company relies on external financing to fund operations, and with a market cap of $710 million, any equity dilution could be substantial. The high cash burn rate (current ratio of 6.76 provides some buffer but is not sustainable long-term).
Market & Competitive Risks: The stock trades at a trailing PS ratio of 42.9x, a 758% premium to the industry average of 5.0x, making it vulnerable to valuation compression if growth disappoints. With a beta of 2.24, it is highly sensitive to macro downturns and sector rotation. The precision oncology diagnostics market is competitive, with larger players like Guardant Health and Natera. The company's reliance on partnership-driven revenue (e.g., pharma collaborations) creates lumpiness, as seen in the volatile quarterly revenue.
Worst-Case Scenario: If revenue growth fails to materialize and losses persist, the stock could re-rate to its historical low PS multiple of 2.8x, implying a price of approximately $1.03 (based on annualized revenue of $61.9 million). This would represent a -93.5% decline from the current price of $15.79. The 52-week low of $3.84 provides a more realistic downside of -75.7%. In this scenario, the company may need to raise capital at depressed prices, further diluting shareholders.
FAQ
The key risks include: 1) Valuation risk: the trailing PS of 42.9x leaves no room for error; 2) Financial risk: persistent losses and negative free cash flow of -$84.65 million TTM; 3) Competitive risk: larger players like Guardant Health and Natera dominate the market; 4) Execution risk: revenue is lumpy and dependent on pharma partnerships. The most severe risk is a valuation collapse if growth disappoints, potentially leading to a 75%+ decline from current levels.
The 12-month outlook is mixed. The bull case (20% probability) sees the stock reaching $16.15-$20, driven by major partnerships. The base case (50% probability) expects a range of $10-$16, with modest revenue growth. The bear case (30% probability) targets $3.84-$8, if revenue disappoints. The most likely scenario is the base case, assuming revenue grows to analyst estimates of $227.4 million. However, the extreme valuation makes the downside risk higher than the upside potential.
PSNL is significantly overvalued relative to its peers and its own history. The trailing PS ratio of 42.9x is far above the industry average of 5.0x and near the top of its historical range of 2.8x to 51.3x. The forward PS ratio of 21.4x (based on estimated revenue of $227.4 million) is still a premium but less extreme. The market is pricing in aggressive growth, which may not materialize given the recent 24.9% revenue decline. The stock appears overvalued, and any disappointment could lead to multiple compression.
Personalis is a high-risk, high-reward stock that may appeal to speculative investors. The stock has strong momentum, with a 150% gain over the past year, and a clean balance sheet (debt-to-equity of 0.15). However, it trades at a trailing PS ratio of 42.9x, which is 758% above the industry average, and the company is unprofitable with declining revenue. The analyst consensus is cautiously optimistic (2 Buy, 1 Hold), but without a clear target price, the risk/reward is unfavorable. It could be a good buy for those willing to bet on a turnaround, but only as a small position in a diversified portfolio.
PSNL is more suitable for short-term trading due to its high volatility (beta of 2.24) and speculative nature. The stock has shown strong momentum, with a 61% gain in one month, but the underlying fundamentals are weak. Long-term investors face significant risk from valuation compression and dilution. A minimum holding period of 6-12 months is recommended for those willing to bet on a turnaround, but the stock should be monitored closely for signs of revenue growth or margin improvement.
